About

The Boston Glycobiology Discussion Group was formed in 1994 as a 501 (c) (3) non-profit corporation. For over two decades, the Boston Glycobiology Discussion Group (BGDG) has brought together academic researchers and industry representatives that share a common interest in glycobiology, glycoanalytics and glycoinformatics. We are a group of over 100 researchers and industry representatives in the Boston metropolitan area with partners at Boston’s prominent research institutions and biotechnology companies. We meet on a monthly basis during the academic year to network, share a meal, listen to a guest speaker present state-of-the-art research related to glycobiology, and engage in a friendly discussion of the speaker’s research.

BGDG comprises of a core board that oversees the proceedings of the group and an industrial advisory board. BGDG officers are elected for two years by a voting process and are responsible for the group's day-to-day activities.

BGDG leadership:

Board:

Prof. Catherine E. Costello (Boston University School of Medicine)

Prof. Joseph Zaia (Boston University School of Medicine)

Prof. Richard D. Cummings (Beth Israel Deaconess Medical Center/Harvard Medical School)

Prof. David S. Newburg (Boston College)

Prof. Gherman Wiederschain (Boston College)


Industrial Advisory Board:

Tom Trainor (Agilent Technologies, Inc.)


BGDG officers:

President: Kevin B. Chandler (Boston University School of Medicine)

Vice-president: Kshitij Khatri (Boston University School of Medicine)

Treasurer: Joseph Zaia (Boston University School of Medicine)

Secretary: Yousuf Aqueel (Boston University School of Medicine)

Member-at-large: Jean Spencer (Boston University School of Medicine)

Member-at-large:  Sylvain D. Lehoux (Beth Israel Deaconess Medical Center/Harvard Medical School)


Comments